TIOTROPIUM BROMIDE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

6,235 reports of this reaction

2.2% of all TIOTROPIUM BROMIDE reports

#8 most reported adverse reaction

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #8 most commonly reported adverse reaction for TIOTROPIUM BROMIDE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 6,235 FDA adverse event reports linking TIOTROPIUM BROMIDE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.2% of all 284,745 adverse event reports for this drug.

TIOTROPIUM BROMIDE has an overall safety score of 78 out of 100. Patients taking TIOTROPIUM BROMIDE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE6,235 of 284,745 reports

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for TIOTROPIUM BROMIDE, but still significant enough to appear in the safety profile.

Other Side Effects of TIOTROPIUM BROMIDE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for TIOTROPIUM BROMIDE:

INCORRECT ROUTE OF DRUG ADMINISTRATION — 23,320 reports
DYSPNOEA — 22,314 reports
ASTHMA — 10,819 reports
DRUG INEFFECTIVE — 9,385 reports
COUGH — 8,610 reports
PNEUMONIA — 8,383 reports
WHEEZING — 6,762 reports
PRODUCT QUALITY ISSUE — 5,971 reports
FATIGUE — 5,361 reports
OFF LABEL USE — 4,664 reports

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

ACETYLCYSTEINE ACLIDINIUM BROMIDE ALBUTEROL ARFORMOTEROL TARTRATE BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE FLUTICASONE PROPIONATE AND SALMETEROL FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE GLYCOPYRROLATE IPRATROPIUM BROMIDE IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE MANGANESE SULFATE ROFLUMILAST SALMETEROL XINAFOATE THEOPHYLLINE THEOPHYLLINE ANHYDROUS TIOTROPIUM BROMIDE INHALATION SPRAY UMECLIDINIUM UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Frequently Asked Questions

Does TIOTROPIUM BROMIDE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 6,235 FDA reports for TIOTROPIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with TIOTROPIUM BROMIDE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.2% of all adverse event reports for TIOTROPIUM BROMIDE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking TIOTROPIUM BROMIDE?

If you experience chronic obstructive pulmonary disease while taking TIOTROPIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

TIOTROPIUM BROMIDE Full Profile All Drugs Causing CHRONIC OBSTRUCTIVE PULMONARY DISEASE Boehringer Ingelheim Pharmaceuticals, Inc. Drugs

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.